Melanoma-Targeted Chemothermotherapy and In Situ Peptide Immunotherapy through HSP Production by Using Melanogenesis Substrate, NPrCAP, and Magnetite Nanoparticles.

Abstract

Exploitation of biological properties unique to cancer cells may provide a novel approach to overcome difficult challenges to the treatment of advanced melanoma. In order to develop melanoma-targeted chemothermoimmunotherapy, a melanogenesis substrate, N-propionyl-4-S-cysteaminylphenol (NPrCAP), sulfur-amine analogue of tyrosine, was conjugated with magnetite nanoparticles. NPrCAP was exploited from melanogenesis substrates, which are expected to be selectively incorporated into melanoma cells and produce highly reactive free radicals through reacting with tyrosinase, resulting in chemotherapeutic and immunotherapeutic effects by oxidative stress and apoptotic cell death. Magnetite nanoparticles were conjugated with NPrCAP to introduce thermotherapeutic and immunotherapeutic effects through nonapoptotic cell death and generation of heat shock protein (HSP) upon exposure to alternating magnetic field (AMF). During these therapeutic processes, NPrCAP was also expected to provide melanoma-targeted drug delivery system.

• Authors: Kowichi Jimbow, Yasue Ishii-Osai, Shosuke Ito, Yasuaki Tamura, Akira Ito, Akihiro Yoneta, Takafumi Kamiya, Toshiharu Yamashita, Hiroyuki Honda, Kazumasa Wakamatsu, Katsutoshi Murase, Satoshi Nohara, Eiichi Nakayama, Takeo Hasegawa, Itsuo Yamamoto, Takeshi Kobayashi
• Journal: Journal of skin cancer (J Skin Cancer) Vol. 2013 Pg. 742925 ( 2013) ISSN: 2090-2905 [Print] United States
• PMID: 23533767 (Publication Type: Journal Article)